Scrip’s Top Five Stories Of 2018
Executive Summary
A look back at the Scrip stories that piqued the most interest for our readers in 2018.
| Table |
|---|
Advertisement
Related Content
Pfizer Consumer Combo Deal Frees Capital For GSK Pharma Investment
‘Drastic’ Japan Price Reforms Hitting R&D Incentives, Plans - EFPIA
AbbVie Defends Humira With Aggressive Discount In First EU Tender
Merck Steps Out Of Insulin Glargine Market, But Says It Remains Committed To Biosimilars
Momenta Is Exiting Biosimilars; Is That A Bellwether For Biosimilar Sentiment?
Who's Promised What: A Guide To Pharma Drug Pricing Pledges
Pfizer Agrees To Roll Back Prices On 40 Drugs, Yielding To Pressure From Trump
Takeda, Shire Finally Seal £46bn Deal
Japan Price Reforms - Major Takeaways
FDA's Gottlieb: 'Pricing And Reimbursement Mischief' Holding Back Biosimilar Market
Topics
- Subjects
- Companies
- Commercial
- Policy & Regulation
- Pricing Strategies
- Pricing Debate
- Industries
- BioPharmaceutical
Related Companies
- Takeda Pharmaceutical Co. Ltd.
- Shire PLC
- GlaxoSmithKline PLC
- Novartis AG
- Sanofi
- Bioverativ Inc.
- Pfizer Inc.
- AbbVie Inc.
- Allergan PLC
- Servier SA
- Celltrion Inc.
- Johnson & Johnson
- Mylan NV
- Amgen Inc.
- Merck & Co. Inc.
- Momenta Pharmaceuticals Inc.
- Roche
- Alcon Inc.
- Aurobindo Pharma Ltd.
- Endocyte Inc.
- Advanced Accelerator Applications SA
- AveXis Inc.
- AstraZeneca PLC
- Amazon.com Inc.
- MedPlus Inc.
- Tesaro Inc.
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SC124411
Ask The Analyst
Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
SC124411
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.